A little-known biotech’s high-stakes cancer bet just paid off and its shares doubled
· cnbc.com · popularity 36/100 · 0 similar stories today · Cancer & Oncology (Health & Life Sciences)
Read the original at cnbc.com →
Summary
Genmab’s shares have doubled in three months after a string of cancer drug trial wins, strengthening its push to own more of the medicines it develops.
Found in: CNBC Top News. Rating basis: single outlet; outlet tier 5; 1 feeds; feed position 16.